Carregant...
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
OBJECTIVE: Low-grade serous (LGS) ovarian and primary peritoneal cancer is a rare disease with limited therapeutic options. Low response rates are observed with cytotoxic chemotherapy. However, significant responses have been reported in patients treated with bevacizumab. The objective of this study...
Guardat en:
| Publicat a: | Int J Gynecol Cancer |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4401424/ https://ncbi.nlm.nih.gov/pubmed/24978709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000190 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|